LEUSTATIN (CLADRIBINE) CLINICAL TRIAL IN CHRONIC PROGRESSIVE MS

$34,535M01FY2000RRNIH

Yale University, New Haven CT

Investigators

Linked publications & trials

Paper 39147159 Paper 38278947 Paper 37292813 Paper 36602867 Paper 35587276 Paper 34320286 Paper 33479058 Paper 33071178 Paper 32064729 Paper 31886931 Paper 31685489 Paper 31418516 Paper 31295359 Paper 31167889 Paper 31118516 Paper 30967435 Paper 29936086 Paper 29872859 Paper 29758564 Paper 29697830 Paper 29427697 Paper 29398050 Paper 29246363 Paper 29157731 Paper 28664624 Paper 28378429 Paper 28199816 Paper 27803118 Paper 27423510 Paper 27411016 Paper 27353125 Paper 27161901 Paper 27074126 Paper 27057209 Paper 26937618 Paper 26892753 Paper 26877127 Paper 26770763 Paper 26628417 Paper 26577415 Paper 26542740 Paper 26537182 Paper 26531295 Paper 26305973 Paper 26080344 Paper 25784663 Paper 25750929 Paper 25702853 Paper 25690268 Paper 25664775 Paper 24948348 Paper 24847862 Paper 24450390 Paper 24378638 Paper 24370654 Paper 24319454 Paper 24135709 Paper 24067395 Paper 23881275 Paper 23704677 Paper 23704676 Paper 23704675 Paper 23704674 Paper 23704673 Paper 23704672 Paper 23656339 Paper 23582593 Paper 23438494 Paper 23400602 Paper 23213072 Paper 22981277 Paper 22926660 Paper 22835646 Paper 22684193 Paper 22644414 Paper 22541894 Paper 22540912 Paper 22525943 Paper 22369102 Paper 22368174 Paper 22332798 Paper 22023165 Paper 21981958 Paper 21972276 Paper 21960671 Paper 21930284 Paper 21836107 Paper 21798559 Paper 21471553 Paper 21398396 Paper 21357794 Paper 21241948 Paper 21156204 Paper 21149431 Paper 21128874 Paper 21102327 Paper 20962220 Paper 20962021 Paper 20929989 Paper 20807062

Abstract

This is a randomized, double-blind, parallel-group, placebo-controlled, multi-center trial to evaluate the safety and efficacy of Leustatin tm (Cladribine) in subjects with chronic progressive multiple sclerosis. There will be three patient groups in the trial: (1) a placebo group: (2) a high dose treatment group, and (3) a low dose treatment group. The placebo group is necessary to establish the magnitude of changes in clinical endpoints that may occur in the absence of active treatment.

View original record on NIH RePORTER →